All In Biotech

Drug Trial Radar · NCT07025018

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Jul 15, 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations

Conditions

  • Gliomas Harboring IDH1 and/or IDH2 Mutations

Interventions

  • HMPL-306Drug

    IDH small molecule inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days after first dose of study drug
  2. RP2DTime frame: From first dose of study drug to the time of progressive disease, assessed up to 24 months on average

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.